Unlock instant, AI-driven research and patent intelligence for your innovation.

Vaccine freeze-drying protective agent

A freeze-dried protective agent and vaccine technology, which is applied to vaccines, veterinary vaccines, medical preparations with inactive ingredients, etc. Restriction and other problems, to achieve the effect of improving heat resistance, prolonging storage time, and improving survival rate

Active Publication Date: 2017-09-19
杭州洪晟生物技术股份有限公司 +1
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The transportation and storage of live vaccines mostly need to be preserved and transported at low temperature. In the current veterinary vaccines, the commonly used protective agents for freeze-dried live vaccines are mainly milk, sucrose, gelatin, etc. The formula is simple and the protection function is poor, resulting in freeze-dried live vaccines. Vaccines have poor heat resistance, and the storage and transportation of freeze-dried live vaccines are limited

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccine freeze-drying protective agent
  • Vaccine freeze-drying protective agent
  • Vaccine freeze-drying protective agent

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1: Vaccine lyoprotectant, in parts by weight, weighed the components in the following Table 1, prepared solutions with ultrapure water, mixed evenly after sterilization, and obtained vaccine lyoprotectant . Among them, the filler is gelatin, the antifreeze is glycerin, the antioxidant is vitamin D, the acid-base regulator is phosphate buffer, and the phosphate buffer is configured as follows: 0.2mol / L sodium dihydrogen phosphate solution and 0.2mol / L 1 L of disodium hydrogen phosphate aqueous solution, weigh 36ml of the above-mentioned sodium dihydrogen phosphate and 14ml of the above-mentioned disodium hydrogen phosphate, and mix them to obtain a phosphate buffer.

[0031] Preparation of freeze-dried live vaccine: Commercially purchased chicken Xincheng La Sota strain and chicken embryos.

[0032] Determination of virus content before freeze-drying: According to the requirements of "Chinese Pharmacopoeia" three (2010): make 10-fold serial dilutions of the toxi...

Embodiment 2

[0036] Embodiment 2: Vaccine lyoprotectant, the difference from Embodiment 1 is that the filler is sucrose, the antifreeze is dimethyl sulfoxide, and the antioxidant is vitamin E. Table 1 lists the virus content before freeze-drying, the virus content after freeze-drying, and the results of the thermal stability test of the freeze-dried vaccine.

Embodiment 3

[0037] Embodiment 3: Vaccine lyoprotectant, the difference from Embodiment 1 is that the filler is mannitol, and the antioxidant is sodium thiosulfate. Table 1 lists the virus content before freeze-drying, the virus content after freeze-drying, and the results of the thermal stability test of the freeze-dried vaccine.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a vaccine freeze-drying protective agent which comprises, by weight, 40-60 parts of fillers, 10-15 parts of anti-freezing agents, 3-10 parts of acidifying or alkalizing agents, 2-15 parts of antioxidants, 20-30 parts of hyaluronic acid and 10-25 parts of polyaspartic acid. The vaccine freeze-drying protective agent has the advantages that the fillers are added into the vaccine freeze-drying protective agent, and live vaccines can be protected in the freeze-drying process. The anti-freezing agents can prevent and decrease formation of crystallization water in the freezing process, and the survival rate of the live vaccines in the freeze-drying process is increased. The antioxidants are added to prolong the preservation time of the freeze-dried live vaccines. The hyaluronic acid and the polyaspartic acid are added into the vaccine freeze-drying protective agent and then mixed, the live vaccines are wrapped to form a protective layer, the heat resistance of the freeze-dried live vaccines is improved, and the preservation time of the freeze-dried live vaccines is prolonged.

Description

technical field [0001] The invention relates to animal vaccine products, in particular to a vaccine freeze-drying protective agent. Background technique [0002] Vaccines are autoimmune preparations for the prevention of infectious diseases made from pathogenic microorganisms such as bacteria, rickettsia, viruses, and their metabolites through artificial attenuation, inactivation, or genetic engineering. According to different production processes, it can be divided into freeze-dried vaccines, liquid vaccines and various adjuvant vaccines. Among them, the addition of protective agents in freeze-dried live vaccines and freeze-drying technology are the key links to ensure the quality of live vaccines. [0003] The transportation and storage of live vaccines mostly need to be preserved and transported at low temperature. In the current veterinary vaccines, the commonly used protective agents for freeze-dried live vaccines are mainly milk, sucrose, gelatin, etc. The formula is s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K47/36A61K47/34A61K47/26A61K47/42A61K47/10A61K47/20A61K47/02A61K47/28A61K47/22A61K47/18
CPCA61K47/02A61K47/10A61K47/183A61K47/20A61K47/22A61K47/26A61K47/28A61K47/34A61K47/36A61K47/42A61K2039/552
Inventor 舒建洪杨芳张宇王晗黄磊周泉丽陈伟杰
Owner 杭州洪晟生物技术股份有限公司